Photodynamic Therapy

  • Nathalie C. Zeitouni
  • Allan Oseroff
  • David J. Najarian


In general terms, photodynamic therapy (PDT) involves the use of a light source to activate a compound (photosensitizer) within malignant cells. The activated compound then transfers its energy to molecular oxygen, which works in a destructive capacity to eliminate the tumor.1


Photodynamic Therapy Basal Cell Carcinoma Roswell Park Cancer Institute Nevoid Basal Cell Carcinoma Syndrome Monitor Anesthesia Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors are sincerely grateful to Anne Paquette, RN, BSN, CCRC, and Michelle McCarthy, RPA-C, for their assistance in preparing this manuscript.


  1. 1.
    Marcus SL, McIntyre WR. Photodynamic Therapy systems and applications. Expert Opin Emerg Drugs. 2002;7:331–334.CrossRefGoogle Scholar
  2. 2.
    Tierney EP, Eide MJ, Jacobsen G, Ozog D. Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes. J Cosmet Laser Ther. 2008;10:81–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008;158:994–999.CrossRefPubMedGoogle Scholar
  4. 4.
    Surrenti T, De Angelis L, Di Cesare A, Fargnoli MC, Peris K. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial. Eur J Dermatol. 2007;17:412–415.PubMedGoogle Scholar
  5. 5.
    Levulan Kerastick. FDA Label (NDA 020-965). 2003. Last accessed February 3, 2009.
  6. 6.
    Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg. 2006;32:1261–1265.CrossRefPubMedGoogle Scholar
  7. 7.
    METVIXIA (methyl aminolevulinate) Cream, 16.8%. FDA Label. 2007.Google Scholar
  8. 8.
    Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. JDD. 2003;2:629–635.PubMedGoogle Scholar
  9. 9.
    Alexiades-Armenakas M, Geronemus R. Laser-mediated photodynamic therapy of actinic cheilitis. J Drugs Dermatol. 2004;3:548–551.PubMedGoogle Scholar
  10. 10.
    Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic Photorejuvenation. Dermatol Surg. 2002;28:742–744.CrossRefPubMedGoogle Scholar
  11. 11.
    Karrer S, Baumler W, Abels C. Long-Pulse Dye Laser for Photodynamic therapy: Investigations in Vitro and in Vivo. Lasers Surg Med. 1999;25:51–59.CrossRefPubMedGoogle Scholar
  12. 12.
    Morton C, Campbell S, Gurg G. Intraindividual right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006;155:1029–1036.CrossRefPubMedGoogle Scholar
  13. 13.
    United Kingdom Summary of Product Characteristics. 2007. Last accessed 1/20/09.
  14. 14.
    Australia Summary of Product Characteristics. 2007. Australian Regulatory Guidelines for OTC Medicines. Last accessed 1/20/09.
  15. 15.
    Horn M, Wolf P, Wulf HC, Warloe T, Fritsch C, Rhodes LE, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003;149:1242–1249.CrossRefPubMedGoogle Scholar
  16. 16.
    Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143:1131–1136.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Nathalie C. Zeitouni
    • 1
  • Allan Oseroff
    • 1
  • David J. Najarian
    • 2
  1. 1.Department of DermatologyRoswell Park Cancer Institute State University of New YorkBuffaloUSA
  2. 2.Department of DermatologyUniversity of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical SchoolSomersetUSA

Personalised recommendations